Nao Fujieda
Overview
Explore the profile of Nao Fujieda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
286
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sato S, Matsushita H, Shintani D, Kobayashi Y, Fujieda N, Yabuno A, et al.
BMC Cancer
. 2022 Apr;
22(1):437.
PMID: 35449092
Background: Regulatory T cells (Tregs) play an important role in the antitumor immune response in epithelial ovarian cancer (EOC). To understand the immune-inhibitory networks of EOC, we addressed the association...
2.
Yabuno A, Matsushita H, Hamano T, Tan T, Shintani D, Fujieda N, et al.
Sci Rep
. 2020 Oct;
10(1):18503.
PMID: 33116254
Serum cytokine and chemokine networks may reflect the complex systemic immunological interactions in cancer patients. Studying groups of cytokines and their networks may help to understand their clinical biology. A...
3.
Sugimoto K, Kakimi K, Takeuchi H, Fujieda N, Saito K, Sato E, et al.
J Vasc Interv Radiol
. 2019 May;
30(6):845-853.e6.
PMID: 31126596
Purpose: Irreversible electroporation (IRE) differs from thermal radiofrequency (RF) ablation, especially in terms of the reparative process in the ablation zone induced. To elucidate this, the systemic immune responses after...
4.
Imai Y, Hasegawa K, Matsushita H, Fujieda N, Sato S, Miyagi E, et al.
Oncol Lett
. 2018 Apr;
15(5):6457-6468.
PMID: 29616115
Expression of immune checkpoint molecules, including programmed cell death protein-1 (PD-1), has been reported on T cells in various types of cancer. However, the expression status of these molecules in...
5.
Hoshikawa M, Aoki T, Matsushita H, Karasaki T, Hosoi A, Odaira K, et al.
Biochem Biophys Res Commun
. 2017 Dec;
495(2):2058-2065.
PMID: 29253566
To establish prognostic biomarkers and to identify potential novel therapeutic targets, we performed integrative immunomonitoring of blood and tumor in patients with resectable pancreatic cancer. Flow cytometry (FC) was employed...
6.
Odaira K, Kimura S, Fujieda N, Kobayashi Y, Kambara K, Takahashi T, et al.
Biochem Biophys Res Commun
. 2016 Aug;
478(3):1298-303.
PMID: 27553282
In addition to the majority of T cells which carry the αβ T cell receptor (TCR) for antigen, a distinct subset of about 1-5% of human peripheral blood T cells...
7.
Futami J, Nonomura H, Kido M, Niidoi N, Fujieda N, Hosoi A, et al.
Bioconjug Chem
. 2015 Sep;
26(10):2076-84.
PMID: 26355635
Humoral immune responses against tumor-associated antigens (TAAs) or cancer/testis antigens (CTAs) aberrantly expressed in tumor cells are frequently observed in cancer patients. Recent clinical studies have elucidated that anticancer immune...
8.
Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, et al.
Cancer Immunol Res
. 2014 Aug;
3(1):26-36.
PMID: 25127875
To understand global effector mechanisms of CTL therapy, we performed microarray gene expression analysis in a murine model using pmel-1 T-cell receptor (TCR) transgenic T cells as effectors and B16...
9.
Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, et al.
Cytotherapy
. 2013 Feb;
15(4):481-91.
PMID: 23391461
Background Aims: Adoptive immunotherapy is emerging as a potent anti-tumor treatment modality; Vγ9Vδ2 T cells may represent appropriate agents for such cancer immunotherapy. To improve the currently limited success of...
10.
Kondo M, Izumi T, Fujieda N, Kondo A, Morishita T, Matsushita H, et al.
J Vis Exp
. 2011 Sep;
(55).
PMID: 21931292
Human γδ T cells can recognize and respond to a wide variety of stress-induced antigens, thereby developing innate broad anti-tumor and anti-infective activity. The majority of γδ T cells in...